Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Oxaliplatin is a major antitumor agent but its use is limited by potentially disabling
neurotoxicity, characterized by a sensitive defect in the extremities.Mangafodipir is a MRI
contrast agent with antioxidant properties. Our previous laboratory works showed that
mangafodipir is able to prevent hematologic toxicity of several chemotherapy agents,
including oxaliplatin and to increase their antitumor activity. Preliminary clinical data
suggested that mangafodipir could prevent oxaliplatin neurotoxicity.The primary purpose of
the present study is to assess the protective effect of mangafodipir in patients who have a
already moderate oxaliplatin neuropathy and in whom the continuation of this treatment is
desirable because of significant antitumor effect.